Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

15.21 +0.48 (+3.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Thera CS

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
Via The Motley Fool
From GLD To TSLA: Unlocking Today’s Best Trading Opportunities
The week kicks off amidst significant market movements shaped by geopolitical and policy developments. 
Via Talk Markets
Topics Stocks / Equities
Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
9 Analysts Have This To Say About Intellia Therapeutics
Via Benzinga
A Glimpse of Intellia Therapeutics's Earnings Potential
Via Benzinga
Looking Into Intellia Therapeutics's Recent Short Interest
Via Benzinga
7 Analysts Have This To Say About Intellia Therapeutics
Via Benzinga
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
There's nothing bearish at all about what it reported recently. 
Via The Motley Fool
This Beaten-Down Stock Could Soar by 354%, According to Wall Street
Maybe the Street is a bit too optimistic on this one. 
Via The Motley Fool
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
A Closer Look at Intellia Therapeutics's Options Market Dynamics
Via Benzinga
3 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Via Benzinga
Expert Ratings For Intellia Therapeutics
Via Benzinga
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Intellia Therapeutics Stock Plummeted by 20% Today
Seemingly encouraging results from the lab were met with some notable skepticism. 
Via The Motley Fool
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses. 
Via Benzinga
This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility. 
Via The Motley Fool
2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street
These stocks haven't performed well this year. 
Via The Motley Fool
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
The Ark Invest portfolio is known for taking aggressive bets. 
Via The Motley Fool
3 Gene Editing Stocks with Potential to Transform Medicine
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. 
Via InvestorPlace
NTLA Stock Earnings: Intellia Therapeutics Misses EPS, Misses Revenue for Q2 2024
NTLA stock results show that Intellia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth-stock investor added to these three existing positions on Wednesday. 
Via The Motley Fool
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
3 Gene Editing Stocks That Could Grow Your Wealth
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks. 
Via InvestorPlace
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
Via InvestorPlace
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
Via Benzinga
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.